Zenas BioPharma, Inc. (ZBIO) shares fell 57.30%, trading at $14.73, down $19.77, even after the company reported positive top-line results from its Phase 3 INDIGO clinical trial.
The decline came on heavy volume following the INDIGO update, which showed that Zenas' investigational therapy met its primary endpoint and demonstrated a favorable safety profile. While the results were clinically encouraging, the market reaction suggests investor concerns may remain around commercial prospects, regulatory timing, costs, or broader sector sentiment.
On the day of the announcement, ZBIO opened near $34.50, saw a high above $35.20, and dropped to a low around $14.50, compared with a previous close of $34.50. The stock trades on the Nasdaq.
Trading volume was well above the average daily level, reflecting heightened activity as shareholders reacted to the clinical data.
Zenas BioPharma's 52-week range spans a wide band, illustrating typical biotech volatility tied to trial readouts and regulatory developments.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.